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Abstract
 
Type I and II interferons (IFNs) exert opposing effects on the progression of multiple sclerosis,
even though both IFNs use the signal transducer and activator of transcription 1 (STAT1) as a
signaling mediator. Here we report that STAT1-deficient mice expressing a transgenic T cell
receptor against myelin basic protein spontaneously develop experimental autoimmune encepha-
lomyelitis with dramatically increased frequency. The heightened susceptibility to this autoimmune
disease appears to be triggered by a reduced number as well as a functional impairment of the
CD4
 
  
 
CD25
 
  
 
regulatory T cells in STAT1-deficient animals. Adoptive transfer of wild-type
regulatory T cells into STAT1-deficient hosts is sufficient to prevent the development of
autoimmune disease. These results demonstrate an essential role of STAT1 in the maintenance
of immunological self-tolerance.
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Introduction
 
Multiple sclerosis (MS) is a T cell–mediated, demyelinating
autoimmune disease of the central nervous system charac-
terized by T cells reactive to the major components of the
myelin sheaths, such as myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein, and proteolipid protein (1).
In animals, MS-like symptoms can be induced by immuni-
zation with MBP or with peptides representing specific
epitopes of proteins associated with the myelin sheats, leading
to the development of experimental autoimmune encepha-
lomyelitis (EAE; 2).
Similarly, MS-like disease symptoms emerge in mice that
express a transgenic TCR against MBP (3) after immunization
of such animals with MBP. In this case, the TCR 
 
  
 
and 
 
 
 
chains were derived from a CD4
 
  
 
encephalomyelitogenic T
 
cell clone that recognizes MBP in an H-2 I-A
 
u
 
–restricted
context. Due to allelic exclusion, 
 
 
 
5% of CD4
 
  
 
T cells in
these animals express antigen receptors of different antigen
specificity. In transgenic mice of H-2
 
u 
 
haplotype, 14% of the
animals develop the disease within 12 mo, whereas no
symptoms arise in an H-2
 
b 
 
background. One of the most
striking discoveries resulted from the cross of MBP TCR
transgenic mice with RAG-1–deficient animals. The RAG-1
protein is required for the successful rearrangement of anti-
body and TCR genes. Thus, in RAG-1–deficient mice,
lymphocytes can only mature if they express functional
antigen  receptors as transgenes. RAG-1–deficient mice
transgenic for the MBP-directed TCR succumb to EAE at a
rate of 100% by 12 mo (4). These findings unequivocally
demonstrate that nontransgenic lymphocytes, which are
absent in the RAG-1–deficient animals, exert a protective
effect against the development of the autoimmune disorder.
One cell population that can mediate a protective effect
 
has been identified as a subset of CD4
 
  
 
T cells that coexpress
CD25, but are distinct from activated T cells (5). Based on
their function, this T cell subpopulation has been termed
“suppressor” or “regulatory” T cells (6–8). Importantly,
 
adoptive transfer of wild-type CD4
 
  
 
cells into RAG-1–
deficient, MBP TCR transgenic mice was found to protect
the animals from developing EAE (9). Once activated,
CD4
 
  
 
CD25
 
  
 
cells act in an antigen-independent manner
(10), and appear to represent a unique lineage of CD4
 
  
 
T
cells, albeit of elusive origin.
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Among several immunomodulatory therapies for MS
treatment, IFN-
 
  
 
administration has become the treatment
of choice. IFNs as well as other cytokines and growth
factors mediate their antiviral and antiproliferative effects
through the induction of immediate early response genes
(11). The signal transducer and activator of transcription 1
(STAT1) transcription factor has been identified as an im-
portant part of the IFN-
 
 
 
/
 
  
 
and IFN-
 
 
 
–induced signaling
cascades (12).
Several years ago, two labs independently generated
STAT1-deficient mice to elucidate the role of STAT1 in
vivo (13, 14). As expected, the most prominent phenotype
was a significantly increased sensitivity of these animals to
viral infections due to their inability to respond to the anti-
viral effects of IFNs. The lack of IFN-mediated up-regula-
tion of MHC expression also results in an inability to mount
an effective immune response to bacterial infections. Inter-
estingly, it appeared that lymphocyte development was not
substantially altered in the absence of STAT1 (13, 14). As
such, STAT1
 
 
 
/
 
  
 
mice display a normal CD4/CD8 profile
in the thymus, and no obvious defects were found in the B
cell compartment. A later report described that splenocytes
derived from STAT1
 
    
 
animals displayed a reduced rate of
apoptosis due to a lack of caspase 1 and 11 expression (15).
IFNs were first used in MS therapy because of their anti-
viral properties, as it has been observed that acute viral in-
fection triggers the onset and clinical relapses of the disease.
Initially, IFN-
 
  
 
was administered, however, the IFN itself
provoked significant exacerbation of the disease (16). This
observation consequently led to the therapeutic application
of IFN-
 
 
 
/
 
  
 
because type I IFNs were known to counter-
act several actions of IFN-
 
 
 
.
The opposing effects of IFN-
 
 
 
/
 
  
 
and IFN-
 
  
 
in the pro-
gression of MS raise the intriguing question as to what role
STAT1 plays in the pathogenic process because both IFNs
use STAT1 as the primary mediator of their biological ac-
tions. To address this issue we used EAE as a model for MS
and examined the effects of STAT1 expression on the in-
duction and progression of this autoimmune disease.
 
Materials and Methods
 
Animals.
 
Wild-type and STAT1
 
 
 
/
 
  
 
129/SvEv (H-2
 
b/b
 
) mice
were purchased from Taconic Inc. and mice expressing the trans-
genic TCR 
 
  
 
and 
 
  
 
chains (TCR
 
 
 
) specific for the MBP
(MBP1-9) were provided by S. Tonegawa (Massachusetts Insti-
tute of Technology, Cambridge, MA). These animals were
crossed to generate STAT1
 
 
 
/
 
  
 
TCR
 
  
 
H-2
 
u/u 
 
or H-2
 
b/u 
 
and
STAT1
 
 
 
/
 
  
 
TCR
 
  
 
H-2
 
u/u 
 
or H-2
 
b/u 
 
mice. All mice used in these
experiments were maintained in a pathogen-free environment
and were bred and cared for in accordance with University of
California San Diego Animal Care Facility regulations.
 
EAE Scoring and Immunizations.
 
Clinical symptoms of EAE
were graded as follows (17): level 0, no symptoms; level 1, limp
tail; level 2, partial paralysis of hind legs; level 3, complete paraly-
sis of hind legs; level 4, paralysis of fore and hind legs; level 5,
moribund. For some experiments, 6–10-wk-old STAT1
 
 
 
/
 
 
 
TCR 
 
  
 
  
 
H-2
 
b/u 
 
mice were immunized with 200 
 
 
 
g MBP per
mouse emulsified in CFA.
 
Flow Cytometry and Intracellular Cytokine Staining.
 
FITC-
labeled anti-CD4 mAb, PE-labeled anti-CD8 mAb, FITC-labeled
anti-V
 
 
 
8 mAb, PE-labeled anti-CD69, biotin-conjugated anti-
CD25 mAb, and biotin-conjugated anti–
 
 
 
/
 
  
 
TCR mAb were
obtained from BD Biosciences. Biotin-conjugated anti-B220,
anti-CD4 mAbs, and APC-conjugated streptavidin were pur-
chased from eBioscience. Anti-CD3
 
  
 
mAb (clone 2C11) and IL-2
supernatant were provided by S. Hedrick (University of Califor-
nia San Diego, San Diego, CA).
For immunostaining, single cell suspensions were prepared
from thymus, spleen, and peripheral lymph node cells. After re-
moving red blood cells, one million cells were resuspended in the
staining buffer (PBS, 1% FCS, 0.02% NaN
 
3
 
) and incubated with
the antibodies for 30 min on ice. For intracellular cytokine stain-
ing, cells were stimulated with 50 ng/ml PMA and 500 ng/ml
ionomycin for 4 h. 10 
 
 
 
g/ml brefeldin A was added during the
last 2 h of the incubation. Stimulated cells were stained with
FITC-labeled anti-CD4 Ab before fixing with 4% paraformalde-
hyde. Cells were resuspended in permeabilization buffer (PBS,
1% saponin, 1% FCS) and stained with PE-labeled anti–IFN-
 
 
 
mAb (BD Biosciences) for 30 min on ice.
 
T Cell and APC Purification.
 
CD4
 
  
 
T cells from spleen and
thymus were isolated by magnetic sorting using magnetic micro-
beads (Miltenyi Biotec). In brief, single cell suspensions were in-
cubated with biotinylated anti-CD8, anti-B220, anti-MAC1,
anti-Gr1, and anti–
 
 
 
/
 
  
 
TCR antibodies (BD Biosciences) for 30
min on ice, washed, and further incubated with anti-biotin beads
(Miltenyi Biotec) for 15 min. Cells were then applied to a Super-
Macs magnet column and CD4
 
  
 
T cells that did not bind to the
Figure 1. Spontaneous EAE development in wild-type and STAT1-
deficient mice. (A) TCR  STAT1 /  H-2b/u  mice and their TCR 
STAT1 /  H-2b/u littermates (30 animals/group) were monitored for 6
mo and the spontaneous development of EAE (level 5) was recorded. (B)
Same as in A, but TCR  STAT1 /  H-2u/u mice and their TCR 
STAT1 /  H-2u/u littermates (20 animals/group) were used. 
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column were collected. This fraction was then stained with PE-
labeled anti-CD25 (PC61) and FITC-labeled anti-CD4 and
FACS
 
® 
 
sorted to obtain CD4
 
  
 
CD25
 
  
 
and CD4
 
  
 
CD25
 
  
 
T cells.
For depletion experiments, CD4
 
  
 
T cells were additionally la-
beled with biotinylated anti-CD25 antibody at the same time and
CD4
 
  
 
CD25
 
  
 
cells were collected. T cell–depleted spleen cells
(TDS) as APCs were obtained by removal of T cells with bio-
tinylated anti-CD4, anti-CD8, and anti–
 
 
 
/
 
  
 
TCR antibodies as
outlined above. APCs were treated with 50 
 
 
 
g/ml mitomycin C
for 30 min.
 
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Assays.
 
CFSE was obtained from Molecular Probes, Inc. Purified T cell
populations of interest were washed and resuspended in PBS con-
taining 5 
 
 
 
M CFSE. After incubation for 8 min, media contain-
ing serum was added and labeled cells were washed and subjected
to proliferation assays. T cells (10
 
6 
 
cells/well) were cultured with
mitomycin-treated TDS (3 
 
  
 
10
 
6 
 
cells/well) as APCs in a 24-well
flat-bottom plate in the absence or presence of 1.0 
 
 
 
g/ml Con A.
After 3 d of incubation, stained cells were analyzed with a FAC-
Scan™ (Becton Dickinson). To analyze the suppressive proper-
ties of regulatory T cells, CD4
 
  
 
CD25
 
  
 
T cells were labeled with
CFSE and cultured in 96-well plates (10
 
5 
 
cells/well) with TDS as
APCs (3 
 
  
 
10
 
5 
 
cells/well), 25 ng/ml anti-CD3 antibody, and the
indicated numbers (1:0, 1:0.1, 1:0.2, 1:0.4, and 1:0.8) of unla-
beled wild-type or STAT1-deficient CD4
 
  
 
CD25
 
  
 
cells. After 3 d
of incubation, stained cells were analyzed with FACScan™ (Bec-
ton Dickinson).
 
Proliferation Assays by [
 
3
 
H]thymidine Incorporation.
 
Purified T
cells (2 
 
  
 
10
 
4 
 
cells/well) were cultured with mitomycin-treated
TDS (6 
 
  
 
10
 
4 
 
cells/well) as APCs in a 96-well round-bottom
plate. For stimulation either 1.0 
 
 
 
g/ml Con A or 50 ng/ml anti-
CD3 antibody in combination with 50 U/ml human rIL-2 were
added. Stimulated cells were cultured in complete medium for 2 d,
pulsed with 1 
 
 
 
Ci [
 
3
 
H]thymidine per well, and harvested 16 h
later. All data shown represent an average of at least three inde-
pendent experiments.
 
Adoptive T Cell Transfer.
 
CD4
 
  
 
T cells or CD4
 
  
 
CD25
 
  
 
T
cells derived from STAT1
 
 
 
/
 
  
 
TCR
 
  
 
H-2
 
b/u 
 
mice were purified as
outlined above, and injected intravenously in 200 
 
 l PBS into
37–41-d-old STAT1 /   TCR  H-2b/u  littermates. Recipient
mice were monitored every other day for EAE development and
progression.
Results
STAT1-deficient Mice Are Highly Susceptible to Autoimmune
Disease. Mice transgenic for an MBP-reactive T cell re-
ceptor and of the required H-2u/u haplotype (4) succumb to
EAE after immunization with MBP. These transgenes were
originally injected into C57BL/6 eggs, and the required
H-2u/u haplotype was introduced into the transgenic back-
ground by crosses with PL/J mice (4). Several reports illus-
trated the need for a homozygous H-2u/u background, as
mice of H-2b/u or H-2b/b genotype failed to develop EAE.
To address the role of STAT1 in autoimmune disease
development, we crossed these transgenic mice onto
STAT1 /  animals with the goal to obtain STAT1-defi-
Figure 2. Flow cytometric analysis of wild-type, asymp-
tomatic, or paralyzed STAT1-deficient mice. (A) Cells
derived from lymph nodes of wild-type, asymptomatic, or
paralyzed STAT1-deficient animals were stained for CD4,
CD69, and V 8. Horizontal axis represents V 8 staining,
vertical axis corresponds to CD4 (top) or CD69 (bottom)
staining of CD8  cells. Cells displayed in lower panels are
CD4 . (B) Splenocytes derived from wild-type, asymp-
tomatic, or paralyzed STAT1-deficient animals were stim-
ulated with 50 ng/ml PMA/500 ng/ml ionomycin for 4 h
(10  g/ml brefeldin A was added during the last 2 h) and
stained for CD4, CD8, and intracellular IFN- . CD4
staining (horizontal axis) and IFN-  production (vertical
axis) of CD8  cells is shown.Role of STAT1 in Autoimmune Disease 28
cient mice bearing the transgenic TCR on an H-2u/u back-
ground. Surprisingly, we observed already in the F2 gener-
ation that several STAT1-deficient animals carrying the
transgenic TCR (TCR  STAT1 /  H-2b/u) spontaneously
developed progressive paralysis, even though these mice
were of H-2b/u genotype.
By the age of 10 wk, 50% of these animals had devel-
oped level 5 paralysis, and by 24 wk 90% of the mice had
succumbed to EAE (Fig. 1 A). In contrast, none of their
TCR  STAT1 /  H-2b/u littermates displayed any symp-
toms. Strikingly, even repeated immunization of TCR 
ST /  H-2b/u mice with MBP was unable to provoke EAE
development, confirming previously published results on
the importance of the H-2u/u background (4).
Identical to mice of H-2b/u genotype, TCR  STAT1 / 
H-2u/u mice succumb to spontaneous EAE at a drastically
increased rate when compared with TCR  STAT1 / 
H-2u/u animals, whereas TCR  STAT1 /  H-2u/u mice also
spontaneously developed EAE at the previously published
frequency (4) of  15% (Fig. 1 B).
Increased IFN-   Production and CD69 Up-regulation in
STAT1-deficient Paralyzed Mice. T cells expressing the
transgenic TCR can be identified by immunostaining
with V 8-specific antibodies (4). To verify that the ab-
Figure 3. Immunohistological anal-
ysis of CNS tissue from asymptomatic
and paralyzed STAT1-deficient
mice. Brains and spines were removed
from asymptomatic or paralyzed
(level 5) STAT1-deficient mice and
fixed in formaldehyde. Paraffin-
embedded  sections were stained
with hematoxylin and eosin.Nishibori et al. 29
sence of STAT1 does not affect the expression of the
transgenic TCR, peripheral lymph node T cells derived
from either 10–12-wk-old asymptomatic or level 4 para-
lyzed TCR  STAT1 /  H-2b/u mice, or from their het-
erozygous littermates, were analyzed for V 8 expression.
As shown in Fig. 2 A, the fraction of CD4  V 8  cells
( 90%) is virtually identical among the three animal
types. Notably, only V 8  cells displayed increased CD69
expression in the paralyzed STAT1 /  mice, whereas no
such up-regulation is observed in CD4  V 8  cells. In ac-
cordance with the manifestation that MS/EAE is a Th1
cell–mediated autoimmune disorder, CD4  T cells from
level 4 paralyzed TCR  STAT1 /  H-2b/u mice displayed
a significant up-regulation in intracellular IFN-  produc-
tion (Fig. 2 B).
Increased Lymphocyte/Macrophage Infiltration in the Central
Nervous System (CNS) of STAT1-deficient Paralyzed Mice.
To ensure that the observed paralysis was indeed the con-
sequence of an inflammatory response of the CNS, brains
and spines were removed from asymptomatic or paralyzed
STAT1-deficient TCR  H-2b/u  mice and subjected to
histopathological analysis after hematoxylin/eosin stain-
ing. As shown in Fig. 3, there is a multifocal to diffuse en-
cephalitis composed of an admixture of neutrophils and
mononuclear cells visible in the brain stem and hippocam-
pus of the paralyzed animals. In addition, the spinal cord
sections of EAE  mice display a focal cavitating necropu-
rulent area at the distal aspect of the section. As such, the
histological analysis confirms the presence of massive in-
flammatory processes and typical EAE lesions in the CNS
of TCR  STAT1 /  H-2b/u mice that had progressed to
level 5 paralysis.
Hyperproliferation of STAT1-deficient CD4  T Cells In
Vitro. Total splenocytes isolated from STAT1-deficient
animals have been shown to hyperproliferate in vitro (15).
To explore specifically the mitogenic behavior of CD4 
cells, these cells were purified from wild-type and
STAT1 /  129/SvEv mice as outlined in Materials and
Methods, and subjected to in vitro proliferation assays in
the presence of mitomycin-treated, wild-type APCs and 1
 g/ml Con A. Under these conditions STAT1-deficient
cells displayed an approximately fourfold increased prolif-
Figure 4. Proliferation of wild-type and STAT1-deficient CD4  cells.
(A) CD4  cells were purified from the spleens of wild-type or STAT1-
deficient mice as described in Materials and Methods, and proliferation
was assessed by thymidine incorporation in response to stimulation with
1.0  g/ml Con A in the presence of mitomycin C–treated APCs. (B)
CD4  cells were purified from the spleens of TCR  STAT1 /  H-2b/u
mice and their TCR  STAT1 /  H-2b/u littermates, and proliferation was
measured by thymidine incorporation. Mitomycin C–treated APCs were
generated from STAT1 /  H-2b/u animals and preincubated with 100
 g/ml MBP as indicated.
Figure 5. (A and B) Flow cytometric analysis of thymocytes in wild-
type and STAT1-deficient mice. Cells derived from thymi of wild-type
or STAT1-deficient animals were stained for CD4, CD8, and CD25. The
ratio of CD4  CD8  CD25  cells as the percentage of total CD4  CD8 
cells is shown.Role of STAT1 in Autoimmune Disease 30
eration rate when compared with their wild-type coun-
terparts (Fig. 4 A).
To confirm this difference in cell growth in T cells ex-
pressing the transgenic TCR and in response to the domi-
nant autoantigen of EAE, CD4  cells were also isolated from
TCR  STAT1 /  H-2b/u mice and their TCR  STAT1 / 
H-2b/u littermates. Mitomycin C–treated APCs were gener-
ated from STAT1 /  H-2b/u animals and preincubated with
100  g/ml MBP as indicated. Similar to nonspecific stimu-
lation by Con A, CD4   T cells derived from TCR 
STAT1 /  H-2b/u  mice responded with substantially in-
creased proliferation in the presence of APCs presenting
MBP antigen, whereas no mitogenesis was observed with-
out APCs or with APCs in the absence of MBP (Fig. 4 B).
Figure 6. Effect of wild-type
CD4  CD25  cells on the pro-
liferation of STAT1 /  CD4 
cells. (A) CD4  cells were puri-
fied from the spleens of wild-type
or STAT1-deficient mice as de-
scribed in Materials and Methods.
Wild-type or STAT1-deficient
CD4   cells were either incu-
bated separately, mixed in a 1:1
ratio, or wild-type cells were
CD25 depleted before mixing
1:1 with STAT1-deficient cells
as indicated. Proliferation was then
assessed by thymidine incorpo-
ration in response to stimulation
with 1.0  g/ml Con A in
the presence of mitomycin
C–treated APCs. (B) Same as in
A, but cells were stimulated
with 50 ng/ml anti-CD3 anti-
body in combination with 50
U/ml human rIL-2. (C) CD4 
cells were purified from the
spleens of wild-type or STAT1-
deficient mice as described in Ma-
terials and Methods. STAT1-defi-
cient cells were labeled with
CFSE and their proliferation in
response to 1.0  g/ml Con A in
the presence of either unlabeled
wild-type CD4   cells or unla-
beled CD25-depleted wild-type
CD4  cells (1:1 ratio) was deter-
mined by flow cytometry. (D)
CD4   cells were purified from
the spleens of wild-type mice, de-
pleted of CD25  cells, and labeled
with CFSE. Proliferation in re-
sponse to 1.0  g/ml Con A in
the presence of either unlabeled
STAT1 /   CD4   cells or unla-
beled CD25-depleted STAT1 / 
CD4  cells (1:1 ratio) was deter-
mined by flow cytometry.Nishibori et al. 31
Reduced Number of CD4  CD25  Regulatory T Cells in the
Absence of STAT1. The dramatically increased frequency
of spontaneous EAE development in TCRMBP-transgenic
STAT1-deficient animals is reminiscent of the phenotype
observed in mice expressing the TCRMBP in the absence of
RAG-1 (4). In this model, a deficiency of CD4  CD25 
regulatory T cells was found to be ultimately responsible for
the lack of immunological self-tolerance (9). Therefore, we
decided to analyze thymic CD4  cells for the presence of
the CD25  subpopulation in wild-type and STAT1 / 
129/SvEv mice. In wild-type animals, 9–10% of the CD4 
cells were CD25 , conforming to previously published
findings. In contrast, only  5% of CD4  cells accounted
for CD25  regulatory T cells in STAT1-deficient animals
(Fig. 5). Similar, albeit smaller differences were observed in
the peripheral lymphoid organs (not depicted). We further
analyzed the CD4  CD25  T cells from wild-type and
STAT1 /  mice for the expression of additional cell surface
markers such as CTLA-4, CD45RB, and CD62L, which
are typical for regulatory T cells, but did not observe any
significant differences between these animals (not depicted).
Wild-type CD4  Cells Suppress the Hyperproliferation of
STAT1-deficient T Cells. The finding of a reduced CD4 
CD25  T subpopulation in STAT1 /  mice raised the
possibility that the hyperproliferation of STAT1-deficient
CD4  cells is due to a loss of the intrinsic suppressor effect
of regulatory T cells. Therefore, we tested whether wild-
type CD4  cells had the ability to restrain the proliferation
of their STAT1-deficient counterparts. CD4  cells were
purified from wild-type and STAT1 /  129/SvEv mice
and subjected to thymidine incorporation assays. As found
previously, STAT1 /   cells displayed an approximately
fourfold increase in the Con A–stimulated mitogenic re-
sponse when compared with wild-type cells. However,
mixing of wild-type and STAT1-deficient CD4  cells in a
50:50 ratio resulted in a proliferation rate significantly
lower than the expected average of the two individual pop-
ulations, suggesting that wild-type CD4  cells exert a sup-
pressive effect on their STAT1 /  equivalents (Fig. 6 A).
To further investigate whether the wild-type CD4  cells
mediate their suppressive function truly through the activi-
ties of CD4  CD25  regulatory T cells, we performed
analogous mixing experiments, this time with wild-type
CD4  cells depleted of their CD25  subpopulation. In-
deed, removal of CD25  cells from the wild-type CD4 
cells resulted in significant reduction in their ability to exert
antiproliferative effects upon STAT1-deficient cells (Fig. 6
A). This finding is not restricted to Con A stimulation, as a
similar pattern of trans-suppression emerged when anti-
CD3 antibodies were used for TCR stimulation in the
presence of exogenous IL-2 (Fig. 6 B). The trans-suppres-
sive effect required the coculture of the CD4  cells from
both animals, as the transfer of conditioned media from
wild-type cells into the cultures of their STAT1-deficient
counterparts was unable to reproduce the antiproliferative
effect (not depicted).
Wild-type, but Not STAT1-deficient CD4  CD25  Cells
Suppress T Cell Proliferation. Next, we wanted to ensure
that the reduced rate of [3H]thymidine incorporation in the
mixed T cell populations was indeed due to a suppressive ef-
fect of the wild-type CD4  CD25  regulatory T cells on the
proliferation of STAT1-deficient cells. To specifically mea-
sure the mitogenic response of only one of the T cell popu-
lations in the mixture, we used CFSE staining to analyze cell
proliferation. CD4  cells were derived from wild-type and
STAT1 /  mice, however, only STAT1-deficient cells were
labeled with CFSE such that only proliferation of these cells,
but not of added wild-type cells, would be monitored. Stim-
ulation with 1  g/ml Con A resulted in a massive prolifera-
tive response of STAT1 /  CD4  cells (Fig. 6 C, panels 1
and 2), which was considerably reduced when unlabeled,
wild-type CD4  T cells were present during the incubation
(Fig. 6 C, panel 3). Removal of CD25  cells from the wild-
type cells before their addition to labeled, STAT1-deficient
cells resulted in a significant, albeit not complete, abrogation
of the antiproliferative effect (Fig. 6 C, panel 4).
Figure 7. STAT1-deficient CD4 
CD25  cells fail to suppress T cell
proliferation. CD4  CD25  and
CD4   CD25   cells were purified
from spleens as described in Materials
and Methods. Wild-type or STAT1-
deficient CD4   CD25   cells were
labeled with CFSE and their prolif-
eration in response to 1.0  g/ml
Con A in the absence or presence
of either unlabeled wild-type or
STAT1-deficient CD4  CD25  cells
was determined by flow cytometry
(ratios of CD4   CD25 /CD4 
CD25  cells were 1:0.1, 1:0.2, 1:0.4,
and 1:0.8 in lanes 3–6 and 10–13,
respectively). A representative of
three independent experiments is
shown.Role of STAT1 in Autoimmune Disease 32
CD4  CD25  T cells can still be found in STAT1 / 
mice, even though their population is  50% reduced com-
pared with wild-type animals. Because it seemed unlikely
that the lower ratio of CD4  CD25  cells alone would ac-
count for the substantial differences in cell proliferation, we
decided to analyze the suppressive ability of the remaining
STAT1-deficient CD4  CD25  cells. Resembling the ap-
proach outlined above, wild-type CD4  cells were labeled
with CFSE after they had been depleted of their own
CD25  subpopulation. Subsequently, proliferation of these
cells was monitored in the absence or presence of unlabeled
STAT1-deficient CD4  cells. Interestingly, the addition of
STAT1 /  CD4  cells was unable to trigger any change in
the proliferation rate of their wild-type counterparts (Fig. 6
D, panels 2 and 3). Accordingly, the removal of CD4 
CD25  cells from the STAT1-deficient population was
also without any effect on the mitogenic response of the
wild-type CD4  cells (Fig. 6 D, panel 4).
To further corroborate these results, we also added in-
creasing numbers of purified wild-type or STAT1-deficient
CD4  CD25  cells to either wild-type or STAT1-deficient
CD4  CD25  cells that had been labeled with CFSE to an-
alyze their proliferation. As shown in Fig. 7, wild-type
CD4  CD25  cells were able to suppress the proliferation
of their wild-type or STAT1-deficient CD25  counterparts
in a dose-dependent manner (striped bars). In contrast,
STAT1    CD4  CD25  cells failed to exert any growth
inhibitory effect on either wild-type or STAT1    CD4 
CD25  cells (dotted bars). These results not only demon-
strate that STAT1    CD4  CD25  cells fail to act as func-
tional regulatory T cells, but also illustrate that STAT1   
CD4  CD25  cells retain their ability to respond to the in-
hibitory effects of wild-type CD4  CD25  cells.
Adoptive Transfer of Wild-type CD4  CD25  Cells Prevents
EAE Development in STAT1    TCR  Mice. To deter-
mine whether the observed deficiencies in CD4  CD25 
regulatory T cell function are indeed responsible for the in-
creased susceptibility of STAT1-deficient mice toward the
development of EAE, we transferred either total CD4  cells
or CD4  CD25  cells derived from TCR  STAT1 / 
H-2b/u into their TCR  STAT1 /  H-2b/u littermates. As
summarized in Table I, 80% of TCR  STAT1 /  H-2b/u
mice developed level 5 paralysis at the age of 17 wk. In con-
trast, mice that had received wild-type CD4  cells succumbed
to the disease at a substantially reduced (32%) rate. This pro-
tective effect was further increased when purified CD4 
CD25  cells were transferred into the TCR  STAT1 / 
H-2b/u mice, illustrating the physiological importance of this
cell population in the protection against EAE.
Discussion
The immunomodulatory functions of IFNs have long
provoked interest in the role of these cytokines in the de-
velopment or treatment of numerous autoimmune disor-
ders, particularly of MS (18). The opposing effects that
types I and II IFNs elicit in the progression of the disease
prompted intense investigation into the underlying mecha-
nism (16). It is generally accepted that MS, as well as the
widely used murine model EAE, represent Th1-mediated
autoimmune diseases in which CD4  cells specific for MBP
trigger demyelination of the CNS with devastating conse-
quences (1). The immune system in STAT1-deficient mice
is skewed toward Th2-type responses (19). Therefore, con-
trary to our observations, a reduced sensitivity toward Th1-
mediated autoimmune diseases would be expected. In-
triguingly, 35% of the CD4  cells in paralyzed TCR 
STAT1 /  H-2b/u mice stained positive for intracellular
IFN- , demonstrating that these animals were able to
mount a strong Th1 response despite their inability to re-
spond to IFN- .
Previous studies have shown that STAT1-deficient cells
lack the expression of several caspase family members (15,
20), thus raising the possibility of an increased susceptibility
toward autoimmune disease due to a defect in the negative
selection of autoreactive T cells in nontransgenic mice.
However, virtually identical numbers of TCRMBP-trans-
genic T cells were found in the peripheral lymphoid organs
of TCR  wild-type and STAT1-deficient animals, making
the possibility of reduced negative selection as the reason for
the increased EAE rate in STAT1 /  mice rather unlikely.
In mice carrying the transgene for the MBP-directed
TCR,   95% of the CD4   cells actually express the
TCRMBP, whereas the remaining cells harbor TCRs of un-
determined specificity. This minor population of phenotypi-
cally nontransgenic CD4  T cells is absolutely crucial for
maintaining immunological self-tolerance, as evidenced by
crosses of the TCRMBP-transgenic mice onto Rag1 /  ani-
mals (4). There, 100% of the animals succumb spontaneously
to EAE due to the complete absence of regulatory T cells.
Further support for the existence of regulatory T cells stems
from the observation that reconstitution of immune-defi-
cient mice with CD4  cells depleted of CD4  CD25  cells
induces autoimmune disease, whereas complementation
with CD4  CD25  cells prevents autoimmune syndromes
elicited by transfer of CD4  CD25  cells (9, 21). Although
the existence of such a “suppressor” T cell population was
originally somewhat controversial, the presence of protective
regulatory CD4  cells is now well accepted (7, 22–26).
Crosses of TCRMBP mice onto STAT1-null mice results
in essentially the same pathological phenotype as the re-
spective cross to RAG-1–deficient animals and is accompa-
nied by a significant reduction in the number of CD4 
Table I. Protection of STAT1    TCR against EAE after 
Adoptive Transfer of CD4  T Cells
Transferred WT cells Lethality after 17 wk (%)
No transfer 24/30 (80)
CD4  (106 cells) 2/6 (32)
CD4  CD25  (5   104 cells) 1/6 (16)Nishibori et al. 33
CD25  cells. Further evidence for a disturbed balance of
CD4  CD25  cells in the absence of STAT1 comes from
the finding that wild-type CD4  CD25  cells are able to
suppress the proliferation of STAT1 /  T cells, whereas
conversely, STAT1-deficient CD4  CD25  cells fail to ex-
ert any effect on CD4  CD25  cells derived from either
wild-type or STAT1    mice. In accordance with previ-
ously published observations that the function of regulatory
T cells requires cell to cell contact, conditioned media from
wild-type T cell cultures was unable to inhibit the exces-
sive proliferative response of STAT1-deficient CD4  cells.
The final proof that diminished CD4  CD25  cell function
accounts for the increased incidence of EAE in the absence
of STAT1 comes from the fact that adoptive transfer of this
cell population from wild-type mice into their STAT1   
littermates protected the host animals against the develop-
ment of the disease.
Many key aspects of the origin of regulatory T cells re-
main unsolved. B7 and CD28 are required elements in the
generation of CD4  CD25  cells (27) as are CD62L (28)
and IL-2 (29). IL-12 is also a crucial factor in the develop-
ment of EAE, as IL-12 /  mice are completely resistant to
the disease (30). The efficacy of type I IFNs in the treat-
ment of MS is likely due to the suppressive effects of
IFN- /  on the IL-12 production by APCs (16). How-
ever, initial theories that IL-12 promotes EAE develop-
ment by inducing IFN-  are contradicted by the finding
that IFN- – or IFN- R–deficient mice still develop EAE,
surprisingly with even higher incidence (31, 32). The latter
finding prompted the hypothesis that IFN-  plays an im-
portant role in the development and activation of regula-
tory T cells (33). The presence and functional integrity
of regulatory T cells in IFN- – or IFN- R–deficient mice
remains to be determined. Intriguingly, a recent study re-
ported that STAT1 and Jak2 expression are significantly in-
creased after TCR stimulation in CD4  CD25  regulatory
cells, but is not affected in CD4  CD25  T cells (34). The
results presented in this work support the notion that
STAT1 signaling might be required for the development
and function of functional regulatory T cells.
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